Status:
NOT_YET_RECRUITING
Memantine as an Additive Therapy in Patients With Traumatic Brain Injury
Lead Sponsor:
Mansoura University
Conditions:
Mild Traumatic Brain Injury
Moderate Traumatic Brain Injury (TBI)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Memantine has shown promise in mitigating secondary brain injury in previous studies. One study demonstrated that early memantine administration in moderate TBI patients resulted in lower serum neuron...
Detailed Description
The current study aims to evaluate the cognitive function, neuroprotective effect, and S-100β serum level effect of Memantine in patients with mild to moderate traumatic brain injury (TBI) patients.
Eligibility Criteria
Inclusion
- Patients between 18 and 70 years of age
- Patients mild (GCS 13-15) to moderate (GCS 9-12) TBI were assessed for the study eligibility.
Exclusion
- Comorbid illnesses, such as diabetes mellitus, ischemic heart disease, acute myocardial infarction within the past 48 hours.
- Acute or chronic renal insufficiency.
- Hepatic diseases.
- Autoimmune diseases.
- Malignancies.
- Pregnancy.
- Patients unable to tolerate enteral feeding.
- More than 24 hours (h) since traumatic injury
Key Trial Info
Start Date :
March 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06914310
Start Date
March 25 2025
End Date
November 30 2025
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University
Al Mansurah, Dakahlia Governorate, Egypt, 35516